Looks like $LOBE has been busy in 2023 Year end financials are out and it looks like 2024 might be the year the stock runs thanks to Altemia, which is the company's first commercial product. It's a medical food for the management of Sickle Cell Disease. Considering the high cost associated to CRISPR's recently approved treatment for SCD, this product seems like a very viable alternative to manage SCD. For the year ended Aug 2023, Altemia sales revenue was $840,531 for 1 quarter, which is impressive considering the sales contract was newly established with Pentec. Also interesting to note is that Lobe will issue 3,000,000 warrants subject to Altemia reaching $20 MIL in cumulative sales.